3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
10
Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Solid Tumors
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Noonan Syndrome
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Lung Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Paclitaxel
6
Carboplatin
6
Gemcitabine
3
pembrolizumab
2
Irinotecan
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
erythromycin propionate-N-acetylcysteinate
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Vemurafenib
1
Surveys and Questionnaires
1
Oxaliplatin
1
HhAntag691
1
Everolimus
1
Etoposide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Unknown Primary
×
cobimetinib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts